The aim: Research of blood lipid spectrum, level of anti-inflammatory cytokines and C-reactive protein of coronary heart disease patients. Materials and methods: There was examined 61 patients with unstable angina, who had been on hospital care in the cardiology department of the Lviv National Emergency Hospital. Their average age was 68.3 ± 1.9 years. The control group included 20 generally healthy persons. There was estimated blood lipid spectrum, C-reactive protein, fibrinogen and proinflammatory cytokine of patients. Results: There was determined considerable increase total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, triglycerides and coefficient of atherogenicity. High level of C-reactive protein and pro-inflammatory cytokines were detected in patients with unstable angina. Conclusions: In patients with unstable angina was revealed a significant increase of proinflammatory cytokines levels in the blood serum: interleukin-1β, interleukin-6, interleukin-17, TNF-α and C-reactive protein, fibrinogen, which indicates activation of the inflammatory process. In patients with unstable angina was detected a significant disorder of blood lipid spectrum. For its correction should be recommended diet and hypolipidemic agents.
The aim – to improve the diagnosis efficiency of patients with arterial hypertension (AH) combined with undifferentiated connective tissue dysplasia (UCTD) based on the study of clinical course, the severity of UCTD external and internal symptoms with determining the levels of IL-1, IL-6, TNF-a, free and general blood oxyproline. Material and Methods. The study implied examination of 90 patients (52 women and 38 men) with AH of stage 2 from first to third degrees with manifestations of UCTD, who were on inpatient treatment in the Cardiology Department of the Lviv City Communal Clinical Emergency Hospital. The mean age of patients was (61.14±2.58) years. Patients were divided into 3 groups depending on the stage and degree of hypertension. Group I (n=16) included patients with hypertension of the first degree, group II (n=35) – with AH of the second degree, group III (n=39) – with AH of the third degree. The control group consisted of 20 patients with hypertension without manifestations of CTD. Patients underwent clinical (checkup, palpation, percussion, auscultation), laboratory (determination of IL-1, IL-6, TNF-a, free and general oxyprolin blood levels) and instrumental studies (ECG, echocardiography, DBPM, ultrasound examination of internal organs and vessels of the lower extremities, ultrasound duplex examination of the carotid and vertebral arteries, radiological examination of the osteoarticular system), consultations of an ophthalmologist, neurologist, traumatologist and dentist. Results. As a result of the study, in the group I of patients (n=16) UCTD of slight degree of severity was revealed in 13 (81 %), of medium degree – in 3 (19 %) persons. In the group II of patients (n=35), UCTD of moderate severity was found in 30 (86 %), severe – in 5 patients (14 %). In the group III of patients (n=39), UCTD of moderate severity was found in 32 patients (82 %), severe – in 7 (18 %). In the study of the level of TNF-a, an increase compared to the control group was detected, particularly, in the group I of patients its level exceeded in 37.4 times, in the group II – in 39.6 times, in the group III – in 46.2 times (p<0.001). IL-1b increased by 2.6-fold (р<0.05) in the group I of patients compared to the control group, 3.1-fold (р<0.01) – in the group II, and by 3.7-fold, that was the foremost (р<0.001), in patients of the group III. In turn, IL-6 in the group I of patients exceeded the indicators of the control group by 4.3 times (p<0.001), in the group II – 4.8 times (p<0.001), in the group III – 5.7 times (р<0.001). The study of the level of free oxyproline revealed its increase in comparison with the control group, namely in the group I of patients exceeded in 6.12 times, in the group II – in 6.81 times, in the group III – by 7.56 times (р<0.01). The study of the general of bound oxyproline revealed its increase in comparison with the control group, namely in the group I of patients exceeded by 6.98 times, in the group II – by 7.79 times, in the group III – by 9.42 times (p<0.01), which indicates an increase in fibrillogenesis and more pronounced destructive and inflammatory processes in connective tissue. Conclusions. Patients with AH of the stage 2 from first to third degrees with manifestations of UCTD have increased levels of IL-1, IL-6 and TNF-a, which are not only sensitive markers of inflammation, but also play an important role in the pathogenesis and progression of vascular lesions, occurrence and destabilization of atherosclerotic plaques and thrombotic vessels occlusion. The determination of blood oxyprolin in patients with hypertension combined with UCTD confirms the presence of CTD, namely the decay of collagen is more pronounced in patients with severe dysplasia.
Hepatoprotectors – drugs that form the basis of pathogenetic treatment of various liver diseases. They help restore impaired hepatocyte function, increase the resistance of liver cells to the effects of pathological factors, enhance the detoxification function of hepatocytes, have antioxidant properties. There is no generally accepted classification of hepatoprotectors today, they are divided into several groups depending on the origin: plant, animal, synthetic origin, products containing essential phospholipids, amino acids, vitamins, and other groups. One of the well-known hepatoprotectors of plant origin is glycyrrhizin – the main active ingredient of licorice root. Licorice root (Glycyrrhiza glabra) is a drug used in medicine since ancient times, as evidenced by historical data from China, Japan, India, Greece, and Europe. Licorice root is widely used today in medicine and the food industry. Glycyrrhizin – potassium and calcium salt of glycyrrhizinic acid, has a wide range of properties. It is used mainly for the treatment of chronic liver disease. In non-alcoholic fatty liver disease, the use of glycyrrhizin helps reduce steatosis, inflammation in the liver has an antifibrotic effect. Studies on the use of glycyrrhizinic acid in hepatocellular carcinoma are actively conducted, as its antitumor properties are known. It is included in the treatment of chronic viral hepatitis. In vitro studies have shown the antiviral activity of glycyrrhizin against HIV-1, SARS-associated virus, respiratory syncytial virus, arboviruses, and its potential for coronavirus control is being discussed. Possibilities of application of glycyrrhizin and cardiovascular diseases are studied. In this article, we present a review of current literature data on glycerol, its properties, and applications in liver disease, other diseases, and our own clinical observations.
Львівський національний медичний університет імені данила Галицького Мета дослідження: визначення ефективності застосування гепатопротектора гепаризину у хворих на нестабільну стенокардію (НС) у поєднанні з неалкогольною жировою хворобою печінки (НАЖХП). Матеріали та методи. Обстежено 42 хворих на НС, серед яких 24 пацієнтів з НС у поєднанні з НАЖХП, 18 хворих на НС і 20 осіб контрольної групи. Пацієнти із поєднаною патологією отримували гепатопротектор. У хворих оцінювали показники ліпідного спектра крові та функціональний стан печінки. Результати. Під час оцінювання ліпідного спектра крові у хворих на НС виявляли дисліпідемію. Після проведеного лікування в обох групах спостерігалося покращення показників ліпідограми. У хворих на НС із супутньою НАЖХП відзначали деяке підвищення рівня трансаміназ та зниження їхнього рівня після проведеного лікування. Заключення. Застосування гепаризину у хворих на нестабільну стенокардію у поєднанні з неалкогольною жировою хворобою печінки позитивно впливало на функціональний стан печінки та сприяло зниженню рівня трансаміназ після проведеного лікування. Суттєвого впливу гепаризину на покращання ліпідного спектра крові не спостерігали. Ключові слова: нестабільна стенокардія, неалкогольна жирова хвороба печінки, ліпідний спектр крові, трансамінази.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.